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Gonadotrophins are mainly known to influence the body through the formation of gonadal 
steroids. However, receptors for luteinizing hormone (LH) and follicular-stimulating hor-
mone (FSH) are present in a set of extra-gonadal tissues in humans and animals, but 
their functional relevance is uncertain. In this article, we present experimental evidence 
that, in T-47D breast cancer (BC) cells, FSH, and LH alter the expression of genes 
involved in adhesion, motility, and invasion through the activation of their receptors. 
Using miniarray technology we also found that LH influences the expression of a broad 
set of genes involved in cancer biology in T-47D cells. Interestingly, the regulatory actions 
of FSH and LH depend on the modality of exposure, with significant differences between 
pre-pubertal-like vs. post-menopausal-like amounts of gonadotrophins, but not after 
intermittent administration, representative of fertile life. We also studied the modulation 
of the circulating levels of gonadotrophins in an in vivo rat model of BC progression and 
observed a direct correlation with the extent of cancer growth. These results support 
the hypothesis that gonadotrophins may have direct effects on extra-gonadal tissues. 
They also highlight that gonadotrophins could potentially contribute to BC progression, 
particularly in post-menopausal women who typically have higher gonadotrophin levels. 
This research may ultimately lead to testing the use of gonadotrophin-modulating drugs 
in BC patients.
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inTrODUcTiOn
In Western countries, breast cancer (BC) is the most prevalent cancer in women. In 2017, it was 
expected that over 252,710 women would be diagnosed with BC in the United States (1). BC is a 
leading cause of death due to the metastatic process (2). In spite of the technological advancements 
in diagnosis and treatment, new strategies as well as new molecular targets are urgently needed to 
fight against BC.
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Hormone-dependent BCs account for 80% of diagnosed cases. 
Postmenopausal women experience the highest risk of developing 
BC (3, 4), notwithstanding the menopause-associated estrogen 
withdrawal. The other endocrine hallmark of menopause is the 
stable elevation of gonadotrophins (5), but the role of these hor-
mones in the incidence of post-menopausal diseases, including 
BC, has received little attention.
Follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH) are glycoprotein hormones that control key steps of human 
and animal reproduction. LH and FSH exert these actions 
through receptors in the ovaries and testes, where they control 
steroidogenesis and gametogenesis (6). During the past decade, a 
scientific debate has arisen around the potential role of gonado-
trophins on the development of BC (7–10). A number of studies 
have indicated that follicular-stimulating hormone receptor 
(FSHR) and luteinizing hormone receptor (LHR) are expressed in 
several cancers, suggesting that gonadotrophins may thus influ-
ence the development or progression of these diseases (11–15).
Our group has recently shown that LHR and FSHR are 
expressed and functional in several BC cell lines, in which 
they modulate migration and invasion through the control of 
rapidly acting signaling cascades triggered by G proteins on 
the cell membrane (15). Cancer cell motility and migration are 
critical steps needed to accomplish invasion and metastasis (16). 
Regulation of the actin cytoskeleton is key in this process; it is a 
tightly regulated event (17). In the presence of LH or FSH, the 
actin-binding protein moesin and the focal adhesion complex 
regulator focal adhesion kinase (FAK) are phosphorylated and 
then localize to the plasma membrane, where they endow cells 
with higher motility through increased adhesion to the extracel-
lular matrix (15, 18). This is mostly driven by the recruitment 
of large intracellular protein complexes, such as the paxillin/
cortactin/N-WASP-Arp2/3 complex, which promote the forma-
tion of molecular bridges between actin, integrins, and focal 
adhesion complexes at specialized cell membrane sites involved 
in cellular motility (17).
The aim of this study was to characterize the modulatory effects 
of FSH and LH on the expression of proteins related to BC cell 
motility and invasion and to couple these findings to functional 
assays. We explored the effects of different types of exposure to 
FSH and LH, such as consistently low, pre-pubertal-like amounts 
or consistently high, post-menopausal-like con centrations, and 
compared them to intermittent low/high amounts, representative 
of the variations in hormone levels that occur during reproduc-
tive years. We also studied the impact of LH on the expression 
of a broad set of genes related to cancer progression using a 
miniarray. Finally, we assessed the influence of LH on BC pro-
gression in vivo.
MaTerials anD MeThODs
cell cultures and Treatments
The human breast carcinoma cell lines T-47D and MDA-MB-468 
were obtained from the American Type Culture Collection. 
T-47D BC cells were grown in RPMI 1640 supplemented with 
l-glutamine (2 mM), 10% fetal bovine serum (FBS), penicillin and 
streptomycin under a 5% CO2 atmosphere at 37°C. MDA-MB-468 
BC cells were incubated in L-15 medium Leibovitz containing 
10% fetal calf serum and l-glutamine, penicillin, and strepto-
mycin. Before experiments investigating genomic effects, the BC 
cell lines were kept 24 h in medium containing steroid-deprived 
FBS. LH (Luveris 75  IU) and FSH (GONAL-f 75  IU) were 
used with three different concentrations. LH and/or FSH were 
obtained from Merck Serono Laboratory. The concentrations 
were chosen to mimic pre-puberty (5 mUI/ml), an ovulatory pat-
tern (5 + 50 mUI–40 h with 5 mUI/ml and 8 h with 50 mUI/ml) 
or postmenopause (50 mUI/ml).
animals
The study used 36 fertile healthy female Wistar rats (weight: 
150–200  g), purchased from Harlan Nossan, Italy. They were 
divided into six groups of six rats each and were housed together 
in a climate-controlled room, with free access to food and water 
and 14 h of illumination (light on at 6:00 a.m. and light off at 
8:00 p.m.). All experimental procedures were approved by the 
Ethical committee of the University of Pisa in accordance with 
the Guide for Care and Use of Laboratory Animals. Virgin 
female rats between 55 and 60 days old received a single subcu-
taneous injection of 14 mg N-nitroso-N-methylurea (NMU)/kg 
body weight (Sigma-Aldrich, St. Louis, MO, USA). NMU was 
dissolved in warm 0.9% NaCl acidified to pH 5.0 with acetic acid 
(vehicle). Control rats received a single i.p. injection of 0.9% 
NaCl solution as vehicle. After 15  weeks of NMU treatment, 
when 24 rats were ovariectomized (OVX) under a tiletamine 
plus zolazepam anesthesia (Zoletil, 1  mg/rat intramuscular). 
Ovariectomy was performed at the same estrous cycle stage, 
as indicated by daily vaginal smears. Active treatments were 
started 4 weeks after surgery. All animals were checked every 
other day for number of breast tumors and size of each tumor. 
FSH, LH, and estradiol were measured at baseline and after 30 
and 60 days.
Groups were as follows:
 (1) Fertile controls: 6 animals that had not been injected with 
NMU were used to control for potential NMU-related changes 
in FSH, LH, or estradiol levels over the 8-week-observation.
 (2) Fertile NMU: 6 NMU-injected, sham-operated animals were 
used to check for hormonal changes and BC progression 
without any further intervention over a 8-week period.
 (3) OVX NMU: 6 NMU-injected, ovariectomized animals were 
observed without any further intervention for 8  weeks for 
tumor progression and hormonal changes.
 (4) OVX NMU +  E2: 6 NMU-injected, ovariectomized ani-
mals received estradiol replacement (0.05  mg/kg/day) for 
8 weeks.
 (5) OVX NMU +  LHRH analog: 6 NMU-injected, ovariecto-
mized animals received a single injection of the LH analog 
Leuprorelin (0.05  IU/kg, which is maintained during a 
period of 30 days).
 (6) OVX NMU + LHRH analog + E2: 6 NMU-injected, ova-
riectomized animals received a single injection of the LH 
analog Leuprorelin along with replacement with estradiol 
(0.05 mg/kg/day) for 8 weeks.
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To evaluate the incidence and latency of tumor formation, 
we have palpated the thoracic and abdominal-inguinal mam-
mary glands weekly starting at 4 weeks post-NMU injection and 
continued every other day for the whole 8-week intervention 
period with documentation of tumor number and size. Upon 
sacrifice at the end of the observation, a histological analysis of 
mammary gland and tumors was performed. Tumor incidence 
was determined as the number of animals with at least one 
palpable tumor or microscopic tumor lesion compared to the 
total number of animals in the group. Latency was calculated as 
the time between the NMU injection and the detection of the 
first palpable tumor.
immunoblottings
Cell lysates were separated by SDS-PAGE assay. Antibodies used 
were: FAK (dilution 1:1,000), p-FAK (Y397, 1:1,000), and moesin 
(clone 38, 1:1,000) (BD Transduction Laboratories, Lexington, 
KY, USA); Thr558-p-Moesin (sc-12895, 1:750), p-FAK-Tyr397 
(sc-11765, 1:500), LHR (H-50, 1:500), FSHR (N-20, 1:500), and 
ACTIN (C-11, 1:1,000) (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA). The blocking step was performed with 1% bovine 
serum albumin (BSA) solution for 30 min at room temperature. 
Primary Abs were incubated overnight and secondary Abs were 
incubated for 1 h with standard technique. Immunodetection was 
accomplished with enhanced chemiluminescence. Chemilumi-
nescence was acquired with a quantitative digital imaging system 
(ChemiDoc™ XRS + System with Image Lab™ software #170-
8265, Biorad, USA). The blots were quantified using the Image J 
software.
cell immunofluorescence
T-47D BC cells were grown on coverslips. Cells were fixed for 
30 min with paraformaldehyde (4%) and permeabilized for 5 min 
with 0.1% Triton. Blocking was performed with PBS containing 
3% BSA for 30  min. BC cells were incubated with antibod-
ies vs. phospho-FAKY397 and phospho-MoesinT558 (1:500, BD 
Transduction Laboratories) overnight at 4°C followed by incuba-
tion with a fluorescein-conjugated goat anti-rabbit/mouse second-
ary antibody (1:200; Vector Laboratories). Texas Red-phalloidin 
(Sigma-Aldrich, St. Louis) was added for 30 min to reveal actin 
and the nuclei were counterstained with or 4′-6-diamidino-
2-phenylindole (Sigma-Aldrich, St. Louis) and mounted with 
Vectashield mounting medium (Vector Laboratories, Burlingame, 
CA, USA). Immunofluorescence images were captured using 
a Nikon Eclipse E200 microscope (Japan) coupled to a high-
resolution 590CU 5.0M CCD digital camera.
gene silencing With rna interference
A synthetic small interfering RNA targeting FAK (siRNA 
SMARTpool FAK, MN-005607) and control siRNA (scrambled 
siRNA D-001810-01-05) was purchased from Dharmacon 
(Thermo Fisher Scientific Inc., USA); and two SureSilencing 
shRNA Plasmid Human LHR and FSHR and the negative control 
with the GFP marker (Cat KH01310G and KH07073G) were 
obtained from SuperArray Bioscience Corporation. As control, 
parallel cells were transfected with empty vector  +  plasmid 
with GFP (for shRNAs) and scrambled siRNAs (for siRNAs). 
The siRNA and plasmids were used at the final concentration 
of 50–75 nM to silence FAK, LHR, and FSHR according to the 
manufacturer’s instructions. T-47D cells (70–80% confluent) 
were transfected using Lipofectamine (Invitrogen) in Opti-MEM 
medium (Invitrogen) and treated 48  h after transfection. The 
efficacy of gene silencing was checked with western analysis and 
found to be optimal at 48 h.
Moesin silencing With antisense 
Oligonucleotides
Moesin silencing was performed with a specific antisense phos-
phorothioate oligonucleotides (S-modified) (PONs, sequence 
5′-TACGGGTTTTGCTAG-3′) complementary to the 1–15 posi-
tion of the human moesin gene-coding region. As control, the com-
plementary sense PON was used (5′-CTAGCAAAACCCGTA-3′). 
PONs transfections were performed in serum-free medium using 
Lipofectamine (Invitrogen, CA, USA) and added to the culture 
medium for 48 h at the final concentration of 50–75 nM. Moesin 
silencing was confirmed through western blot analysis 48 h after 
transfection.
cell Migration assay
T-47D cells were plated in 6-well plate and grown to 70–80% con-
fluence. Wounds were made in the monolayers by scratching the 
surface with a razor blade, pressing through the confluent T-47D 
cell monolayer into the plastic plate to mark the starting line. BC 
cells were swept away on one side of that line. Cells were washed, 
and 2.0  mL of RPMI 1640 containing steroid-deprived FBS 
added. Cytosine β-D-arabinofuranoside hydrochloride (Sigma) 
(10  µM), a selective inhibitor of DNA synthesis that does not 
inhibit RNA synthesis was used and replaced after 24 h to prevent 
cell proliferation (so to discern the actions of the gonadotrophins 
on movement from those on cell proliferation). Furthermore, 
absence of cell proliferation and viability of the cells were checked 
in preliminary experiments with MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] tests. Migration was 
monitored for 48 h. Cells were digitally imaged and migration 
distance was measured by using phase-contrast microscopy and 
the distance was quantified using Image J Software.
cell invasion assay
Cell invasion was determined using the BD BioCoatTM growth 
factor reduced (GFR) MatrigelTM Invasion Chamber (BD 
Bioscience, USA). After rehydrating the Matrigel inserts, the test 
substance was added to the wells and the chambers were incu-
bated for 48 h. After this, non-invading cells were discarded from 
the upper surface of the membrane using cotton-tipped swabs. 
Then the cells on the lower surface of the membrane were stained 
with Diff-Quick. Invading cells were observed and photographed 
under the microscope at 100× magnification (Nikon Eclipse E200 
coupled to a high-resolution 590CU 5.0M CCD digital camera). 
Cells were counted in the central field of triplicate membranes.
Bromodeoxyuridine (BrdU) cell 
Proliferation assay
The T-47D cells were plated at 5 × 104 cells/well in RPMI 1640 
with 10% FBS, penicillin, and streptomycin in 96-well culture 
FigUre 1 | Continued
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plate. After seeding, the medium was changed to RPMI sup-
plemented with 2% FBS, penicillin, and streptomycin. Then, 
the BC cells were cultured for 48 h, in the presence or absence 
of the following treatments: LH (5, 5 +  50, and 50  mUI/ml), 
FSH (5, 5  +  50, and 50  mUI/ml). BrdU incorporation into 
DNA was subsequently detected by immunoassay using a BrdU 
incorporation assay kit (Chemicon International). In brief, the 
cells were incubated at a concentration of 10 µM of BrdU for 4 h. 
After removal of the culture medium, the cells were fixed and 
incubated with anti-BrdU–peroxidase conjugate for 90 min. The 
cells were then incubated with a tetramethyl-benzidine substrate 
until color development was sufficient for photometric detection. 
The reaction was quantified by measuring absorbance using a 
spectrophotometer microplate reader set at dual wavelength of 
FigUre 1 | Modulatory effects of gonadotropins on breast cancer (BC) cell expression/activation of follicular-stimulating hormone receptor (FSHR), LHR, moesin, 
and focal adhesion kinase (FAK). Protein extracts from (a) T-47D (estrogen-receptor positive) and (e) MDAMB-468 (estrogen-receptor negative) BC cells treated for 
48 h with increasing concentration of LH and follicle-stimulating hormone (FSH) (5, 5 + 50, and 50 mUI/ml) were assayed using western blot analysis for their overall 
content of LHR, FSHR, moesin, p-MoesinT558, FAK, p-FAKY397, and actin. (B–D,F–h) LHR, FSHR, moesin, p-MoesinT558, FAK, p-FAKY397 densitometry values were 
adjusted to actin intensity, respectively, then normalized to the control sample. *P < 0.05 vs. corresponding control. The experiments were performed in triplicates 
and representative images are shown.
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FigUre 2 | LH/follicle-stimulating hormone (FSH) promote breast cancer (BC) cellular migration. (a) T-47D BC cells were treated with LH and FSH in different 
concentrations (5, 5 + 50, and 50 mUI/ml) for 48 h. Horizontal cell migration was measured as the number of cells crossing the starting line or as the mean 
migration distance from the starting line. Sample images of horizontal migration in the different conditions are shown; the black lines indicate the mean migration 
distances. (B) Mean cell numbers or mean migration length is shown. Results are expressed as the mean ± SD of three separate experiments. *P ≤ 0.05 vs. 
control. (c) Effect of a 48-h exposure to LH and FSH on DNA synthesis of T-47D cells, as quantified by the bromodeoxyuridine assay. Data shown are  
representative of three independent experiments.
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450/550  nm (MULTISKAN EX; Thermo Scientific, Lafayette, 
CO, USA).
cell Treatment and rna Preparation
T-47D BC cells were cultured as previously described in Section 
“Cell cultures and treatments.” After incubation for 24  h, the 
supernatant was removed, and the fresh RPMI 1640 containing 
LH in different concentration (5, 5 + 50, and 50 mUI/ml) was 
added into the cell culture, and the cells were incubated for fur-
ther 48 h. After removing supernatant, RNA was extracted with 
the use of Total Isolation Kit (GA-013, SuperArray Bioscience 
Company) according to the manufacturer’s protocol. RNA quality 
was evaluated by running a sample with an RNA loading dye on 
a 1% agarose gel and inspecting for distinct 18S, 28S, and tRNA 
bands (Sigma-Aldrich), indicating lack of degradation; quantity 
was determined by A260 measurement. Samples were frozen at 
−80°C until use in SuperArray.
Microarray analysis
5 µg of RNA of human BC cells T-47D was reverse-transcribed 
with Biotin-16-dUTP (Roche Life Science) using the SuperArray 
TrueLabeling-AMP 2.0 kit (SuperArray, Inc., Frederick, MD, 
USA) according to the manufacturer’s instruction. The result-
ing biotinylated cDNA probe mixture was allowed to hybridize 
overnight to the Human BC Biomarker Gene Array (Cat no: 
OHS-402, SuperArray, Inc.) at 60°C overnight according to 
the manufacturer’s protocol. After washing and blocking array 
membranes, alkaline phosphatase-conjugated streptavidin was 
allowed to bind and the CDP-Star substrate (SuperArray, Inc., 
Frederick, MD, USA) chemiluminescence, and results were visu-
alized. The results were quantified using a Quality One Analyzer 
software (Quantity One; BioRad, Hercules, CA, USA). All signal 
intensities were blank (negative control) DNA background 
subtracted, and normalized to the housekeeping gene actin-beta 
(ACTB) (positive control). Scatter plots were made from normal-
ized signals. Relative gene expression levels were calculated as the 
ratio of the mean of all ACTB signals of all experiments and the 
mean of ACTB of each membrane. The relative expression level 
of each gene was based on the ratio of ACTB in untreated cells 
(CON). Changes in gene expression were illustrated as a fold 
increase/decrease. The cut-off induction determining expression 
was increased more than five times or less than five times. Genes 
which suited both the criteria were considered to be upregulated 
or downregulated. Statistical analysis of the data was performed 
FigUre 3 | LH/follicle-stimulating hormone (FSH) signal to moesin and focal adhesion kinase (FAK) via LHR/follicle-stimulating hormone receptor (FSHR).  
(a–c) T-47D breast cancer cells were transfected with shRNA vs. LHR and FSHR (shRNA LHR and shRNA FSHR) or with vehicle, and protein analysis for LHR, 
FSHR, actin, wild-type (FAK and moesin), or p-FAK and p-moesin was performed on cell lysates after treatment with LH and FSH in different concentrations  
(5, 5 + 50, and 50 mUI/ml) for 48 h. (B,D) The graphs display the quantitative analysis of the intensity of the bands, obtained as number of photons measured  
by the ChemiDoc digital imaging system and evaluated with the Quantity One Software (Bio-Rad).
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using one-way analysis of variance (ANOVA) followed by Tukey–
Kramer Multiple-Comparisons Test.
hormone assays
Serum concentrations of LH, FSH, and estradiol (E2) were deter-
mined by immunoenzymatic method (ELISA). The measures 
are expressed as pmol/l for LH and FSH and nmol/l for E2. For 
each hormone, all samples were analyzed in the same assay and 
performed on different times, which corresponded to before E2 
and/or LH analog administration (T0), at 30 (T30) and 60 (T60) 
days after E2 and/or LH analog administration.
Tissue harvest
Rat mammary glands were collected at 27 weeks post-treatment 
with NMU. In group 1–6 (n = 6), right abdominal-inguinal mam-
mary glands were surgically removed by using anesthesia. Finally, 
these animals were sacrificed and the contralateral glands were 
collected.
immunohistochemistry
Tumors larger than 0.5  cm in diameter were removed from 
the mammary gland and fixed in 10% phosphate buffered 
formalin and processed for paraffin embedding as described 
previously (19). Both the primary tumors as well as the meta-
static lesions underwent immunohistochemical staining using 
an antibody raised against LH and FSH receptor (LHR 1:200 
and FSHR 1:150).
statistical analysis
All values were expressed as mean ±  SD. Statistical analyses 
and graphics were done using InStat from GraphPad Prism 
program version 5.0 Software (San Diego, CA, USA). Statistical 
differences between mean values were determined by ANOVA, 
followed by Tukey–Kramer Multiple-Comparisons test. Values 
of *P < 0.05 indicate significant differences between the groups. 
All values are expressed as mean ± SD.
resUlTs
lh and Fsh regulate Moesin and  
FaK Protein expression in Bc cells
We have recently demonstrated that multiple BC cell lines 
express functional LH and FSH receptors, including MCF-7, 
MDA-MB-231, and T-47D (15). Our first objective was, therefore, 
to determine the actions of LH and FSH exposure on the control 
FigUre 4 | Continued
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of two actin cytoskeleton regulator proteins, moesin, and FAK, 
in BC cells. We treated T-47D (estrogen-receptor positive, ER+) 
BC cells for 48 h with three different concentrations of LH and/
or FSH. The concentrations were chosen to mimic pre-puberty 
(5  mUI/ml), an ovulatory pattern (5 +  50  mUI/ml–40  h with 
5  mUI/ml and 8  h with 50  mUI/ml), and postmenopause 
(50  mUI/ml), respectively. Moesin and FAK phosphorylation, 
which represents functional activation, and overall expression 
FigUre 4 | Gonadotrophins’ signaling to moesin and focal adhesion kinase (FAK) increase T-47D cell migration and invasion. Breast cancer cells were transfected 
with 100 nM target shRNA for LHR and follicular-stimulating hormone receptor (FSHR), siRNA for FAK and 75 nM target phosphorothioate oligonucleotides 
antisense vs. moesin for 48 h and then treated with LH and/or follicle-stimulating hormone (FSH) (5 + 50 mUI/ml) for 48 h. (a,B) Cell migration distances were 
measured as mean migration distance (μm) ± SD. *P ≤ 0.05 vs. control. The experiments were performed in triplicates and representative images are shown.  
(c–h) Cell invasion was assayed using invasion chambers. Average of invading cells observed, photographed under the microscope at 100× magnification and 
counted in three different central fields of triplicate membranes. *P ≤ 0.05 vs. control. The experiments were performed in triplicates. Invasion indexes and 
representative images are shown.
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were increased by exposure to 5 or 5 +  50  mUI/ml with both 
gonadotrophins, whereas no increase or a frank decrease was 
seen with 50  mUI/ml of LH and/or FSH (Figures  1A–D). 
A parallel increase in LHR and FSHR expression was observed 
with 5 and 5 + 50 mUI/ml FSH or LH, with a decline to basal 
levels with 50 mUI/ml (Figures 1A–D). No additive effect was 
seen when gonadotrophins were administered simultaneously 
(Figures 1A–D).
We used estrogen-receptor negative (ER−) MDA-MB-468 
BC cells to distinguish between the effects of gonadotrophin 
and estradiol. The response of LHR, FSHR, moesin, and FAK 
expression to LH exposure was more visible than that of FSH 
(Figures 1E–H).
We also examined the sub-cellular localization of p-moesin 
and p-FAK with immunofluorescence related to the exposure to 
LH and/or FSH (5 + 50 mUI/ml). BC cells treated with LH or 
FSH displayed p-moesin and p-FAK translocation to the mem-
brane, accompanied by a membrane thickening (Figures S1A,B 
in Supplementary Material). Blockade of moesin or FAK with 
specific antisense PONs or siRNAs abrogated the gonadotrophin-
induced membrane activation as well as p-moesin and p-FAK 
translocation to the plasma membrane.
lh and Fsh Promote Bc cell Migration
We performed horizontal migration assays to identify the 
relevance of moesin/FAK activation and expression induced by 
LH/FSH on BC cell movement. Treatment with LH and/or FSH 
(5 + 50 mUI/ml) for 48 h significantly increased the number of 
BC cells that migrated through the starting line, as well as the 
mean length of migration compared to control (Figures 2A,B).
In addition, we checked the action of LH and/or FSH on BC 
cell proliferation. Treatment with LH and FSH did not change 
cell proliferation at any of the concentrations tested (Figure 2C).
lh and Fsh Modulate Moesin-FaK 
expression and activation Through  
lhr and Fshr
To determine whether the gonadotrophin receptors LHR and 
FSHR are involved in LH/FSH-induced moesin and FAK expres-
sion and activation, we blocked their expression with specific 
shRNA. Blockade of LHR and FSHR completely abolished LH/
FSH-dependent moesin and FAK activation and expression in BC 
cells (Figures 3A–D).
intracellular events linking regulation  
of lhr and Fshr to cell Migration  
and invasion
We further investigated the specific action of LHR/FSHR and 
moesin/FAK on BC cell migration and invasion. LH and FSH 
(5 +  50  mUI/ml) markedly increased horizontal migration 
(Figures  4A,B). Silencing of LHR and FSHR with specific 
FigUre 5 | Continued
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shRNAs completely prevented this effect (Figures  4A,B). 
Increased BC cell migration induced by LH and FSH was 
also reduced by blocking moesin and FAK with specific 
antisense PON and siRNAs, respectively (Figures  4A,B). 
In addition, LH and FSH (5  +  50  mUI/ml) promoted BC 
cell invasion of a three-dimensional matrix (Figures 4C–H). 
The invasion induced by LH and/or FSH was prevented by 
silencing LHR, FSHR (Figures  4C–F), moesin, and FAK 
(Figures 4G,H).
effect of e2, lh, and Fsh on Mammary 
cancers in Female rats
In order to understand the in  vivo action of LH and FSH in 
BC cells, we determined the regulation of LH, FSH, estradiol 
(E2), and Leuprorelin (LH analog) in mammary tumors 
induced by NMU, a chemical carcinogen in rats (Figure  5A). 
We used six experimental groups: (1) Rats treated with vehicle 
(Control); (2) Rats treated with NMU; (3) Rats treated with 
NMU and ovariectomized (OVX) to simulate a menopau-
sal condition; (4) Rats treated with NMU, ovariectomized, 
and injected with Leuprorelin (to reduce LH levels); (5) Rats 
treated with NMU, ovariectomized, and treated with estradiol; 
and (6) Rats treated with NMU, ovariectomized, and injected 
with Leuprorelin and estradiol (Figure 5A). Twenty-seven weeks 
after the beginning of the protocol, we observed tumor formation 
in rats treated with NMU, NMU + OVX, NMU + OVX + LH 
analog, NMU + OVX + E2 and NMU + OVX + LH + E2 analog, 
but not in those injected with vehicle. We found a reduced tumor 
formation in the NMU +  OVX group, but even more so with 
Leuprorelin (NMU +  OVX +  LH analog group). In the latter 
group, tumor size was significantly decreased compared to NMU 
alone (Figures 5B,C).
In parallel, we determined plasma levels of LH, FSH, and 
E2 in the study animals at different times (T0, T30, and T60, see 
Figure  5A) (Figure  5D). As expected, ovariectomized animals 
(NMU + OVX) had significantly lower E2 levels and higher LH 
and FSH concentrations (Figures  5D–G). E2 administration 
(NMU + OVX + E2) resulted in a normalization of E2 and LH 
plasma levels, whereas FSH was still slightly increased com-
pared to controls (Figures  5D–G). Leuprorelin administration 
to OVX animals (NMU +  OVX +  LH analog) was associated 
with a reduced peripheral concentration of both gonadotro-
phins (Figures  5D–G). Additionally, administration of E2 in 
FigUre 5 | Continued
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FigUre 6 | Expression of LHR and follicular-stimulating hormone receptor (FSHR) in breast tumors induced by N-nitroso-N-methylurea (NMU). (a) LHR and (B) 
FSHR expression in control (normal ovary tissue) and mammary tumors induced NMU in Wistar rats. Histological sections (4 mm) from normal ovary tissue and 
mammary tumors were used to identify the expression with immunochemistry. (c) Inmunohistochemical analysis of LHR and FSHR by means of the intensity of 
expression and percentage of cells with a positive stain in the different conditions in mammary tumors.
FigUre 5 | Regulation of E2 and LH in mammary tumors induced by N-nitroso-N-methylurea. (a) Reports a visual synthesis of the different treatment schedules  
in female rats. (B) Average tumors per rat, tumor number, and tumor size (ΔT1 = T30/T0 and ΔT2 = T60/T0) after 31 weeks of treatment in rats injected with NMU.  
(c) Tumor size vs. ΔT (ΔT = 60 days) was measured for each tumor. (D–g) Plasma levels (mean + SD) of E2 (nmol/l), LH (pmol/l), and follicle-stimulating hormone 
(FSH) (pmol/l) in fertile-control, NMU, NMU + OVX, NMU + OVX + LH analog, NMU + OVX + E2, or NMU + OVX + LH + E2 analog female rats. The statistical 
differences between mean values were determined by one-way analysis of variance (ANOVA), followed by Tukey–Kramer Multiple-Comparisons test. Values of 
*P < 0.05 indicate significant differences between NMU (a–c) and Control (D–g).
12
Sanchez et al. LH/FSH Affect Breast Cancer Motility
Frontiers in Endocrinology | www.frontiersin.org May 2018 | Volume 9 | Article 239
NMU + OVX + LH analog animals normalized the circulating 
levels of E2 but did not restore FSH levels (Figures 5D–J).
expression of lhr and Fshr in  
Mammary Tumors in Female rats
To understand the extragonadal regulation of LHR and FSHR in rat 
mammary tumors induced by NMU, we analyzed the expression 
of LHR and FSHR in rat ovary (internal control) and rat mam-
mary tumors with immunohistochemistry. We found cytoplasmic 
expression of both receptors in all tumor specimens, particularly 
in epithelial but also in some stromal cells (Figures 6A–C).
Different expression set for cancer-
related genes in human Bc cells  
Upon Different Types of lh Treatment
Finally, we used a colorimetric miniarray targeting more than 
100 genes of established relevance for cancer progression. Of all 
the genes studied (Supplementary Material), we further analyzed 
those closely related to BC progression (Figure 7).
The analysis of the results revealed a marked downregulation 
of genes related to migration–invasion after treatment with LH5 
and LH50. These genes are involved in cell adhesion (CD34 and 
CDH1) or extracellular matrix regulation (such as ADM, INS, 
ERBB2, COL4A2, TGFa, etc.), protein kinases (CDK2, AKT1, 
ATM, EGFR, etc.), proteases etc., and are critical for cell motil-
ity (Figure 7, red colored genes). This downregulation suggests 
that the cells are losing the essential proteins to adhere to the 
substrate, providing a greater migratory and invasive phenotype.
The second noteworthy trend was an upregulation of other 
genes involved in extracellular matrix remodeling (MMP11, 
MMP9, MATN3) and of other protein kinases (KIF14, KIF21A, 
KIF3B, and MYRIP) after treatment with LH5 + 50 (Figure 7, 
green colored genes). The marked upregulation of the metal-
loproteinases MMP11 and MMP9 suggests that the extracellular 
matrix may have been actively degraded, thus favoring migration.
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FigUre 7 | Microarray analysis of effects of LH on the expression of genes related to breast cancer biology. Different set of genes upregulated or downregulated, 
after LH treatment. Changes in gene expression are illustrated as fold increase/decrease. The cut-off induction determining expression was selected as an increase 
or decrease in expression of more than five times or more than two times as compared to untreated cells. Genes that suited the above criteria were considered to 
be upregulated or downregulated or to be moderately upregulated or downregulated, respectively, and they were arranged in different sets (Figures S1C–E in 
Supplementary Material).
The results also revealed eight different sets of genes, grouped 
based on their expression levels, that were triggered by 48 h of 
treatment with LH according to the three previously described 
patterns (5, 5 + 50, and 50 mUI/ml, respectively) (Figures S1C–E 
in Supplementary Material).
DiscUssiOn
Women <40 years usually have more aggressive BC tumors and a 
more unfavorable prognosis than older patients (20). Approxima-
tely one-fifth of affected women will die regardless of advances 
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in screening, diagnosis, and treatment (21). Chemotherapy is 
fundamental in BC treatment although antineoplastic drugs 
may cause severe adverse and toxic effects (22). Although 
malignant breast tumors generally respond to initial chemo-
therapy, intrinsic or acquired multidrug resistance may restrict 
BC treatment and response to therapy (23, 24). Approximately 
90% of deaths in BC patients occur through the development 
and growth of metastases at distant sites (25). It is, therefore, 
vital to develop alternative therapies to prevent or improve the 
prognosis of this disease.
The hormonal environment within the breast affects the 
development and progression of BC (26). We have recently dem-
onstrated that increased LH and FSH levels could be essential to 
increase migration and invasion of BC cells (15). In the present 
study, we identified a novel signaling pathway by which LH and 
FSH receptors signal to moesin and FAK, which in turn could 
increase the ability of LHR/FSHR+ T-47D BC cells to migrate 
and invade the surrounding environment.
Cell motility is a complex and highly orchestrated process 
induced by multiple signaling molecules and implemented by 
actin rearrangement (27). The actin-binding protein moesin is 
critical for the reorganization of actin fibers that control the for-
mation of membrane protrusions at the leading edge (15, 28–31). 
Cellular adhesion to the extracellular matrix also requires the 
development of focal adhesion complexes integrated by proteins, 
such as the integrin-binding proteins paxillin, vinculin, and talin, 
as well as c-Src, and FAK kinases (16). FAK phosphorylation/
activation on Tyr397 is central for this process (32).
Our study revealed that LH and FSH regulate moesin and 
FAK expression and phosphorylation on Thr558 and Tyr397, 
respectively, leading to actin cytoskeleton remodeling and 
formation of focal adhesion complexes. FAK has recently been 
recognized as a main regulator of cell movement, particularly 
during tumor spread. This kinase is positively related to 
metastatic behavior. It is overexpressed in different types of 
cancer, such as endometrial (33), lung (34), melanoma (35), 
and ovarian (36). In human BC, FAK promotes cell motility 
and invasion via N-WASP (18), and increased levels of FAK 
expression are correlated with aggressive phenotype (37). 
In parallel, ablation of FAK activity in a rat BC metastasis model 
inhibited cancer dissemination to the lung (38). Blocking 
FAK in mouse and human mammary tumor cells induces cell 
senescence and loss of its invasive ability (39). These findings 
emphasize the importance of FAK activity and expression for 
cancer metastasis. The discovery of a control of FAK by gon-
adotrophins may thus offer novel insights to better understand 
the action of these hormones on BC metastasis.
It is also interesting to note that isolated BC cells respond 
in different ways to distinct patterns of exposure to FSH or 
LH. Both moesin and FAK activation, as well as the expression 
of a large set of genes related to BC growth and progression, 
are differentially modulated when FSH or LH are provided at 
continuously low (such as before puberty), continuously high 
(such as after menopause), or with an artificial sequence of a 
low concentration followed by a shorter exposure to a high con-
centration (grossly mimicking an ovulatory pattern). Indeed, 
gonadotrophins are known to act through pulsatile stimulation 
of their receptors in the ovary. This finding is, therefore, not 
surprising and consolidates the hypothesis that extragonadal 
gonadotrophin receptors may work similarly to those in the 
gonads.
In addition, we have shown that LHR and FSHR are also 
expressed in mammary tumors induced by NMU in rats. Their 
level of expression was constant in all experimental conditions 
(Figures 6A,C). One limitation of this experiment is the absence 
of LHR and FSHR immunostaining in mammary tissue of the 
control animals. It would be interesting to study whether the 
expression of both receptors is unregulated compared to a mam-
mary cancerous tissue. Our in vivo results also indicate that the 
reduction of circulating amounts of gonadotrophins has a clear 
positive impact on breast tumor growth that is independent of 
estrogen concentrations.
In conclusion, this manuscript suggests that gonadotrophins 
play an important regulatory role on migration/invasion pro-
cesses of BC cells and mammary tumors of female rats. This set 
of actions is related to the recruitment of cytoskeletal controllers 
and to a broader set of genes involved in BC progression. This 
observation is interesting in view of the fact that BC is more 
frequent in postmenopausal women in whom serum gonado-
trophin levels are higher (40). If this were true, a space for using 
drugs that decrease the circulating amounts of FSH and LH, 
such as gonadotrophin-releasing hormone receptor antagonists 
(GnRH-R antagonists) may exist in postmenopausal women, 
with the potential to either decrease the development of BCs 
or to help in controlling cancer progression. Indeed, GnRH-R 
antagonists are commonly used in fertile women and in men 
to treat hormone-dependent tumors, but they are only thought 
to work through the secondary suppression of steroid synthesis 
(41–47). This has been confirmed by our animal work. Our study 
opens the possibility that FSH and LH suppression may be rel-
evant per se in certain tumors. It would, therefore, be interesting 
to test the efficacy of these drugs in postmenopausal women.
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